NewLimit

NewLimit

HealthSan Francisco, United States

NewLimit is a longevity biotech startup focused on reversing cellular aging through epigenetic reprogramming. The company aims to develop drugs that reset gene expression in aged cells, with plans to start human clinical trials in 2027 targeting alcohol-related liver disease. This funding round has significantly increased its valuation, reflecting strong investor confidence in its innovative approach.

$435M · Series CVisit website ↗

Funding history

  1. $435MSeries C2026-06-03
    Source: news.google.com ↗

Founder

Brian Armstrong
Brian Armstrong
CEO & Co-founder

Investors in NewLimit

Backers from this company's tracked funding rounds.

  • Founders Fund
  • Thrive Capital
  • Kleiner Perkins

More Health companies

Recently funded startups in the same category.

Related on Datapile

NewLimit — Health startup in San Francisco, United States | Datapile